News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Specialty Drug Delivery Firm Integral Biosystems, LLC to Participate in Massachusetts Biotechnology Council, Inc.'s MA CRO/CMO Symposium in Newton, Massachusetts on February 25, 2013


2/21/2013 9:45:32 AM

(PRWEB) February 20, 2013 -- Integral BioSystems LLC, led by 20+ year veteran of drug formulation development Shikha P. Barman, Ph.D. and VP of Operations/Intellectual Property Dave Karasic, Esq., will be on hand to answer questions about the firm and its capabilities. The Massachusetts CRO/CMO Symposium, organized by MassBio, is designed to bring together the biopharmaceutical industry and the Massachusetts CRO/CMO cluster. The event will showcase the roles these types of partnerships are playing in accelerating drug development.

Integral BioSystems’ niche is in nano-engineered drug delivery systems aimed at providing solutions to long-held issues in drug products, especially in low drug absorption by target tissues due to cell impermeability and insolubility. In addition to assisting drug companies in developing their dosage forms, Integral scientists are also working on novel solutions to improve the bioavailability of Class II, III and IV compounds.

The Company has developed numerous dosage forms for ophthalmic, oral, sublingual, intranasal, IV and transdermal routes. Integral BioSystems has a translational approach to drug development, customizing delivery systems to achieve the biologically effective objectives of the therapy. Dosage forms are customized to achieve sustained release or targeted, tissue-focused delivery or fast-release/instant delivery, depending upon the desired product attributes.

Once the drug-containing formulations are tested in preclinical models, the Company develops an integrated CMC plan to systematically transition the project to scale up and product development. As part of product development, Integral BioSystems specializes in efficiently developing a dosage form to manufacture and test in Phase I/Phase II first-in-man trials for proof-of-concept. The Company has a network of manufacturers/analytical houses for pharmaceutics that can fast-track the manufacture and release of the sterile dosage form for first-in-man trials.

The Company business model is based on the following corporate objectives: (a) to be a collaborating partner in formulation development/drug product design for start-up and small companies, taking concepts from the laboratory to the clinic, (b) to re-formulate approved drugs for better efficacy and safety profiles, (c) to be a collaborating partner with API synthesis companies to develop generic drug product formats and (d) offer corporate legal services such as contract development/negotiations, patent filings and assessment of IP portfolios.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES